{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Number of participants with partial or complete response by Bladé criteria where partial response is defined as a \\>= 50% decrease in serum paraprotein or 90% decrease in urinary light chains (for participants without measurable serum paraprotein). Complete response is defined as negative serum and urine immunofixation and a bone marrow aspirate with \\< 5% plasma cells.","groups":[{"description":"Subjects will be started on recombinant interferon-α at a dose of 3 million units SQ daily, escalating the dose by 1 million units every week as tolerated to a maximum dose of 3 million units/m2/day. Following a minimum of one month of interferon therapy with two weeks on a stable dose, subjects will begin recombinant interleukin-6 therapy at a dose of 2.5 ug/kg/day.\n\nrecombinant interferon-α\n\nrecombinant interleukin-6","id":"OG000","title":"Interleukin-6 and Interferon-α"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 5 months","title":"Response Rate as Assessed by Number of Participants With Partial or Complete Response by Bladé Criteria.","type":"PRIMARY","unitOfMeasure":"Participants"}